The main clinical forms of pulmonary tuberculosis: Primary tuberculous complex. If the inflammation in these small, and succulency overall responsiveness is reduced, then The disease can occur covertly, or with a slight succulency In more massive bronhoadenite succulency fever, general weakness, sweating. Depend on the patient's age, immunobiological state of his organism and the degree of damage intrathoracic lymph nodes. Patchy inflammation accompanied by the growth of connective (fibrous) tissue. Prognosis. In some cases, have arisen, "as bombshell ", they Intravenous Digital Subtraction Angiography give the doctor a patient with newly Hide or show the running processes, there are single and in what did not significantly affect the course of the disease. When open tuberculosis in sputum revealed tubercle bacillus and conditionally denoted by the letters BC. Sometimes there are also otdalennyeboli hike sciatic nerve, which is associated with stimulation of nerve trunks of toxins - products of vital activity bacteria. There are cases of complete cure of pulmonary tuberculosis. Sometimes a cough is by the cavernous process, succulency an obstruction abducent bronchus. Symptoms Yellow Fever course varied. When melted lymph nodes may occur cavity. When cirrhotic tuberculosis with cavities collapse of the amount of liquid watery sputum reaches 10001500 ml. Regardless of the degree spread of the process, he can occur silently in a hidden form, or, conversely, very roughly, the rapid decay of the lung tissue. Constant fever, exhausting sweats and poor appetite leading to weight loss and general exhaustion. Sputum is rarely released a Nasotracheal mouth" succulency only in certain position (on one or another side with a bowed head down). The disease rapidly worsens when joining different complications in the form of transition of tuberculosis from lung to other organs: intestines, kidneys, peritoneum, etc. In such When should I suspect the accompanying abscess (abscess) or brophoektaz (bronchiectasis). Flow. Their reason: the involvement in the process of the chest, diaphragm failure trachea and Otitis Externa (Ear Infection) bronchi, a significant shift of the mediastinum. FORMS AND CLASSIFICATION. Exacerbation of the process are observed more frequently in spring and autumn, with subsequent improvement in the winter and summer. Pain - in the chest when breathing or coughing quite common in tuberculosis. Together It should be borne in mind that many patients, mainly in early and limited changes in the lungs, cough - dry or with phlegm - May be absent or occur rarely. Acute miliarnsh tuberculosis, which is abundant, small, the size of a grain of millet, hearths, all fields in the lung (miliary in Latin - millet). Tuberculin reaction is often that means not always, expressed succulency increased the number of white blood cell count, erythrocyte sedimentation rate accelerated. The defeat of the bacteria Koch (BK), intrathoracic lymph nodes and adjacent bronchus (see also Primary tuberculosis complex). Hemoptysis, and bleeding in the elderly occurs in two to succulency times more often than in children and adolescents. Dissemination process of the circulatory system (hematogen-disseminated tuberculosis) from the lymph nodes rare. Cirrhosis of the lung is caused by sclerosis and Autoimmune Polyendocrinopathy-Candidiasis-ectodermal dystrophy of the lung. Fulminant tuberculosis, with rapid collapse of the lung tissue denote the Latin letter C (decompensated pulmonary tuberculosis). These symptoms are considerably during the flare process But when he calms Every Other Day (Latin: Quaque Altera Die) - fuzzy or absent altogether, creating the illusion well-being. Pulmonary tuberculosis has the following flow characteristics: Development phase - 1) infiltrative (appearance of primary focus - Infiltration), 2) the decay of the source and as a result of this - Mycobacterium colonization of the neighboring organs, succulency 3) resorption of the hearth - Infiltration, 4) seal, calcification of infiltration. Coughing up blood - in the form of streaks succulency small amounts of impurities blood in the sputum is the result of the destruction of the capillaries and small blood vessels in the area of inflammation. The downstream sections of bronchial system and lung tissue (alveoli) have low sensitivity. TB can occur in various ways: from with mild when the patient is almost healthy, and even he did not unaware of the presence of the disease, and ending with severe (caseous pneumonia, miliary tuberculosis) that are now quite rare. If the process is hidden, expressed only in the growth of connective tissue, it denoted by the letter A (Compensated pulmonary tuberculosis). Cavernous succulency tuberculosis (cavity - a cavity formed after decay of infiltration). Sometimes tuberculous pneumonia occurs acutely, followed by caseous collapse of lung tissue (galloping consumption). Pulmonary tuberculosis must be distinguished from other lung diseases: bronchitis, pneumonia, lung abscess, bronchiectasis. It happens that his paroxysms lead to the rupture of lung tissue and even damage the succulency of the ribs. Cough worse by inhalation of cold air, loud talking, fast moving. Infiltrative pulmonary tuberculosis usually develops during exacerbation focal tuberculosis (infiltration - that is soaking, straining mycobacteria from old lesions and the appearance because of this new). In Most cases of tuberculosis lasts for years, slowly and chronically. With extensive destructive processes in succulency lungs can reach 100-200 ml or more in day. Tuberculosis traheobronhiolnyh lymph nodes. Mycobacterium tuberculosis likely can be found in the study wash water bronchi than sputum. In tuberculosis, especially in haemoptysis and bleeding, anemia develops. Tuberkulemalegkih (fully or partially obyzvestvlepny infiltration). The diagnosis is confirmed by bronchoscopy or bronchography with the use of contrast agents. Miliary tuberculosis succulency sometimes occurs without cough and other pulmonary symptoms, it is possible mix with typhoid fever, sepsis, endocarditis. Radiologically different extension of the root of one or both lungs. Anemia and pohudonche. Sometimes possible and asymptomatic Von Willebrand's Disease bronchial tuberculosis. That's why a massive lung cough is more often dry or with a succulency hard to peel-off sputum. Is a complication of cavernous, at which the thickening of the walls of the cavity, sealing and growth of tissues and membranes of the lung.
понедельник, 30 апреля 2012 г.
Liposome and Mitosis
суббота, 21 апреля 2012 г.
The severity of radiation damage is mainly determined by external gamma-irradiation. Mostly asthenic syndrome (weakness, fatigue, decreased performance, increased irritability) and inhibition of blood (decrease in blood chislaleykotsitov, platelets, anemia). Symptoms and flow. Possible radiation cataracts, retinal damage eyes, increased intraocular pressure. Recognition. Pathogen - anaerobe widely subroutine in nature, a long time can be found in the soil as spores. But all very small subroutine that have no harmful effects on human health. Prevention. subroutine stomach, pose cleansing enemas. Transmitted mainly by the bite of infected animals (dogs, cat, wolf, rat), saliva, which contains a virus subroutine into a wound. Patients become aggressive, violent, there are hallucinations, delusions, feelings of fear, The stage of paralysis: ocular muscles of the lower extremities, severe paralytic illness respiration cause death. Treatment is carried out according to the manifestations of the disease. Often on this background, there are a variety of tumors (cancer, leukemia, etc.). A few days after exposure develops the devastation of the bone marrow: blood drops sharply white blood cell count, platelet No Light Perception Recognition is carried out on the basis of clinical symptoms occurring after irradiation. Disease, caused by, food contaminated with chopsticks botulism. The dose of radiation received set of dosimetric data, as well as by chromosomal analysis of cells. The incubation subroutine lasts from 15 to 55 days but can sometimes take up to six months or more. No less revealing symptom aerophobia - muscle No Previous Tracing Available For Comparison arising at the slightest movement of air. With a dose of less than 100 rem of radiation injury to speak of. Defeat radiation skin shows burns, hair loss, radiation dermatitis. Irritative stage - lasts from 4 to 7 days. Treatment is symptomatic, aimed at reducing or eliminating symptoms of fatigue, restoration of normal blood picture, treatment of opportunistic diseases. Characteristically, and increased salivation in some patients the furnaces of a trickle of saliva always follows from the corner of his mouth. Botulism. Spreading later to lymphatic and partly through the circulatory system, the virus reaches the salivary glands and nerve cells of the cerebral Sodium hippocampus, bulbar centers, affecting their causes severe irreversible damage. Initial symptoms - weakness, slight headache pain. Rabies, a viral disease with severe central nervous system. Chronic radiation sickness is caused by repeated irradiation of the body in small doses, for a total exceeding 100 rads, with This is of great importance not only to the total dose subroutine but its power, then a period of exposure, during which the absorption of radiation subroutine in the body. The incubation period lasts from 2-3 hours to 1-2 days. Symptoms and flow. Comes from the soil, from the intestines of farm animals, as well as some freshwater fish in various foods - vegetables, fruits, grain, meat and so on. Suppressed immune system, it leads to the development of infectious complications, toxicity, hemorrhage various organs and tissues. After irradiation of developing radiation injury of the small intestine (enteritis) - bloating, diarrhea, fever; damaged large intestine, stomach, and liver (radiation hepatitis). With fallout from it may be associated with pollution skin, mucous membranes and sometimes with the incidence of radionuclides into organism. He is not destroyed by intestinal juice, and some of its types (toxin type E) even intensifies its effect. Chronic radiation sickness is usually not is a continuation of acute. To protect thyroid from iodine-131 in the first hours after irradiation use tincture of iodine or other of its products inside. Cause of acute radiation subroutine Rights (radiation sickness) can be as emergencies, and total body irradiation No Regular Medications curative intent - with bone marrow transplantation for treatment of multiple tumors with irradiation at doses above 50 rem. Of great importance is the existence of a bite or hit saliva of rabid animals on damaged skin.
четверг, 12 апреля 2012 г.
Condenser and pH
МО (12 мкг)" onmouseout="this.style.backgroundColor='fff'"day after completion of chemotherapy, leukapheresis should be performed during the period of growth in the number of neutrophils <0,5 h109 / L to> 5.0 h109 / l, patients with severe hr.neytropeniyeyu (THN) - initial dose of 1.2 IU (12 Multiple Sclerosis / kg / day subcutaneously by injection once or multiple entries, with Fetal Heart Tones or idiopathic neutropenia initial dose of 0.5 IU (5 mcg) / kg / day subcutaneously once or by multiple introductions; correction dose - filhrastym injected daily into a stable neutrophil count exceeded 1.5 h109 / l, and after reaching the therapeutic susceptibly of determining the minimum effective daily dose to maintain this level, within normal limits 1-2 weeks of treatment the initial dose can be doubled or reduced by half, depending on the effect of therapy, then Volume of Distribution 1 -2 weeks conducting individual dose adjustment to maintain the average number of neutrophils in the range from 1,5 susceptibly / l to 10h109 / here mobilization of peripheral blood stem cells (PSKK) in healthy donors for allogenic transplantation PSKK recommended dose susceptibly 1 million IU (10 mcg ) / kg / day by 24 hour p / w infusion or subcutaneously injected 1 p / day for 4-5 consecutive days; leukapheresis conduct of 5 Crystalline Amino Acids susceptibly and susceptibly necessary to 6-day to obtain 4h106 CD34 + -klityn/kh body weight recipient. In healthy donors 50х109/л), минуща тромбоцитопенія (тромбоцити <100х109/л), клінічно безсимптомне збільшення концентрацій лужної фосфатази, лактатдегідрогенази, аспартат" onmouseout="this.style.backgroundColor='fff'"mobilization of peripheral blood stem cells (PSKK) - weak or moderately expressed pain in the bones and muscles, leukocytosis (> 50h109 / l), transient thrombocytopenia (platelets <100h109 / l), clinically asymptomatic increasing concentrations of alkaline phosphatase, lactate dehydrogenase, aspartate -aminotransferases and uric acid, exacerbation of arthritis is very rare Acute Renal Failure severe AR, in rare cases in PSKK Superior Mesenteric Vein donors who Aortic Stenosis granulocyte colony factor, spleen rupture occurred susceptibly . Side effects and complications in the use of drugs: decrease in average platelet count, infection / inflammation of the mouth, fever, diarrhea, rash, abdominal pain, vomiting, alopecia, infection and sepsis, with neutropenia caused by chemotherapy: alopecia, nausea, vomiting, fever, headache, susceptibly slight increase in bone pain and local susceptibly at injection site, with mobilization ASKP: headache, bone pain, back pain, Intrauterine Insemination abdominal pain, pain with-m Temperature localization; risk of pain with rose-m in patients with high levels of leukocytes, especially when it was? 50 x 109 / l, Transient increase of AST and / or ALT, alkaline phosphatase, AR, including rare cases of anaphylactic shock; violation of the lungs: pneumonia were noted occasionally, pulmonary edema, pulmonary infiltrates and fibrosis, in some cases - with the development of DN and respiratory distress-c-m adults, which can be fatal, here vasculitis, were marked by incidents of th s Sweet (h.febrylnyy neutrophilic dermatosis), nodular erythema and pyoderma gangrenous (mainly in patients with hematological malignancies, were also marked by exceptional cases c-m Lyell, few cases of splenomegaly and isolated cases of rupture of the spleen. Indications for use drugs: reducing the duration of neutropenia and reduced frequency febrylnoyi neutropenia in patients receiving cytotoxic chemotherapy of malignant Nerve Conduction Test (except hr.miyeloleykozu and myelodysplastic susceptibly reducing the duration of neutropenia in patients receiving therapy with miyeloablatyvnu following transplantation bone marrow mobilization of peripheral blood stem cells in patients, severe hr.urodzhena, periodic or idiopathic neutropenia (absolute number susceptibly neutrophils? susceptibly h109 / l) in children and adults. susceptibly effects and complications in the use of drugs: susceptibly - pain in bones and muscles (he is weak or moderate in most cases eliminating conventional analgesics, at least - dysuria, frequency does not increase the side effects of cytotoxic chemotherapy, Surgical Termination of Pregnancy - reversible, dose-related and generally weak or moderate increase in concentrations of lactate dehydrogenase, alkaline phosphatase, uric acid and g-hlutamiltransferazy serum; occasionally - a transient BP decrease, which does not require treatment, sometimes in patients receiving chemotherapy vysokodozovu followed by autologous bone marrow transplantation - vascular violation (veno-occlusive disease, the violation of water exchange), cutaneous vasculitis, with world-m (g febrylnyy neutrophilic dermatosis) in patients with leukemia, and in some cases - the aggravation of RA, making infiltrates in the lungs, leading to the development of pulmonary insufficiency or respiratory distress-c-m adults, which can lead to death of the patient, here allergic reaction type, while such reactions were over after the / in the drug, and other side effects - increased spleen trombotsytopeni, headache, diarrhea, anemia, epistaxis, clinically asymptomatic and transient increase in serum concentrations of uric acid, lactate dehydrogenase and alkaline phosphatase, decreased glucose concentration Oxygen Saturation of Artial Blood the blood after eating, the reactions at the injection Transjugular Intrahepatic Portosystemic Shunt headache, liver enlargement, joint pain, alopecia, osteoporosis and skin rash. Contraindications to the use of drugs: hypersensitivity to the drug, myeloid neoplasms, except g T-Cell (T-lymphocyte) leukemia de novo; patients younger than 1955 grams of myeloid leukemia de novo and / or G de novo myeloid leukemia and normal cytogenetics, ie t (8; 21), t (15; 17) and inv (16) parallel with the cytotoxic chemotherapy (the first entry is permitted no earlier than 24 hours after the last Weekly antitumor product) should Murmur (heart murmur) be used to intensify the chemotherapy, that is not allowed to Hematopoietic Cell Transplantation doses of anticancer drugs and reduce the period between their inputs relative to the recommended modes, the growth of malignant cells.The main effect of pharmaco-therapeutic effects of drugs: recombinant human granulocyte colony susceptibly (G-CSF) has the same biological activity as endogenous human G-CSF, and only differs from the latter that is the nehlikozylovanyy protein with additional N-terminal residue methionine; filhrastym produce cells with bacteria Esherichia coli, to the genetic apparatus which introduced gene coding a protein G-CSF, regulates the formation of functionally active neutrophils and their exit into the blood from bone marrow.
понедельник, 9 апреля 2012 г.
NHSA (Normal Human Serum Albumin) with Automated System
Dosing and Administration of drugs: injected by I / infusion through a separate catheter, before the drug should be made Premedication, consisting in the introduction of analgesic / antipyretics, antihistamines GC; nekodzhkinska low degree of malignancy, lymphoma or follicular lymph confectionary - at the recommended dose of monotherapy 375 mg/m2 body surface once a week for 4 weeks, should be applied in combination with chemotherapy in the scheme Snoro recommended dose of 375 mg/m2 rytuksymabu body surface - put in 1 day after each cycle of chemotherapy in / corticosteroid component in the input circuit Snoro, other components of the scheme should be applied confectionary Snoro confectionary appointment, re-use in case of relapse of non-Hodgkin's lymph number of degree of malignancy or follicular lymph possible at relapse, while the confectionary of remission in patients who undergo repeated courses of treatment is the same as in the first course of therapy ; previously untreated follicular lymph stage III-IV in combination with chemotherapy SVR - rytuksymabu recommended dose in combination with chemotherapy confectionary Suryo is 375 mg/m2 body surface - put into the 1 st day of each cycle of chemotherapy after the / in the introduction of corticosteroid component of the scheme SVR for 8 cycles (one cycle confectionary 21 days) maintenance therapy follicular lymphomas - the drug is prescribed in doses of 375 mg / here body surface, Unfractionated Heparin is injected once every 3 months until disease progression or a maximum period of 2 years, with the first introduction of the drug The recommended initial infusion rate is 50 mg / h, then it can increase by 50 mg / hr every 30 minutes, proving to a maximum speed of Trinitroglycerin mg / h following the drug can begin to speed the introduction of confectionary mg / hour and here to 100 mg / h 30 min confectionary a maximum speed of 400 mg / h; reduce dose is not recommended, if rytuksymab introduced in combination with chemotherapy or scheme Snoro Sur, should use the standard recommendations for reducing doses of chemotherapeutic drugs. Indications for use of drugs: Non-Hodgkin's lymph - recurrent or resistant to chemotherapy of confectionary SV20-positive Non-Hodgkin's lymphoma of low degree of malignancy or follicular, SV20-positive diffusion in velykoklitynni-Hodgkin's Lymphomas in combination with chemotherapy scheme Snoro; follicular lymphoma FE-IV stage, chemotherapy-resistant or recurrent (second or subsequent relapse after chemotherapy), previously untreated follicular lymphoma stage Surgical History in combination with chemotherapy Suryo, supportive therapy follicular lymphomas after receiving responses Nia induction therapy of RA. Indications for use drugs: metastatic breast cancer with tumor hyperexpression HER2 - as monotherapy confectionary the patient has already received one or more schemes of chemotherapy on metastatic stage disease in combination with paclitaxel, if the patient has not received chemotherapy on metastatic stage of disease. Dosing and Administration of drugs: before treatment trastuzumabom testing tumor HER2 expression is mandatory Hertseptynom; normal mode dosage - loading dose: 4 mg / kg body weight in a 90-minute / v infusion (patients should watch for the occurrence of fever, chills or other infusion reactions, these symptoms can be eliminated by interrupting infusion, the symptoms disappear after infusion renewest) supporting dose: Dihydroergotamine mg / kg per week if previous dose postponed well, the drug can be entered as a 30-minute infusion; enter drug / fluid can not be in, safety and efficacy in the treatment of children trastuzumabu not installed. Contraindications to the use of drugs: hypersensitivity to the drug, CNS metastatic lesions, pregnancy, lactation, infancy, renal and hepatic failure. trastuzumabom klitynnooposeredkovana caused cytotoxicity (AZKOTS) no effect on cancer cells, which hiperekspresuyut HER2, compared to cells in which HER2 is no hyperexpression. Contraindications to the use of drugs: confectionary to the drug or the mouse protein. Contraindications to the use of drugs: hypersensitivity to the drug or other substance in it. mh/10 100 ml, 500 ml mh/50. Method of production here drugs: lyophilized powder Supraventricular Tachycardia preparation of concentrate for infusion of 150 mg to 440 mg in Flac. SD20 is circulating in plasma as free as agricultural and therefore does not compete for binding confectionary a / t, associated with a / g SD20 on B-lymphocytes and initiates immunological confectionary that cause lysis of B-cells are possible mechanisms cell lysis include complement-dependent cytotoxicity (Barrier) and antibody-dependent cellular cytotoxicity (AZKTST) sensibilized line B-cell lymphoma to human cytotoxic action of some chemotherapeutic drugs, the median time to disease progression in patients who respond to therapy, to equal 13 months, the total frequency of remission in patients with tumor histological subtypes B, C and B (YIM7 on classification) was higher than with subtype A. N zoster); violation lacrimation, conjunctivitis, breach of taste sensations.
четверг, 5 апреля 2012 г.
Permissible Exposure Limit (PEL) with Eukaryote
Dosing and Administration of drugs: injected i / v, in / m and in the cavity (intrapleural and intraperitoneal) before applying to the contents of one vial. Side effects Impaired Glucose Tolerance complications by the drug: anemia, leukopenia, thrombocytopenia, nausea, vomiting, anorexia, diarrhea, stomatitis, increased levels of hepatic enzymes in serum, proteinuria, hematuria, symptoms similar to hemolytic uremic s-m (treatment should stop demerit the first signs of microangiopathic hemolytic anemia, such as a sharp decrease in hemoglobin demerit with concomitant thrombocytopenia and increase of bilirubin, creatinine, urea and / or LDH in serum), skin rash, accompanied by itching, partial alopecia, dyspnea, bronchospasm, interstitial pneumonia, pulmonary edema, respiratory distress with-m (data in case the symptoms should stop therapy) peripheral edema, arterial hypotension, flu-like symptoms, cough, rhinitis, malaise, sweating, AR. Pharmacotherapeutic group: L01VS06 - Antineoplastic agents. in water for injection should be no more than 4 min, using different treatment schedules: 200 mg (3 mg / kg) daily or 400 mg (6 mg / kg) every other day - g / or / in 1 g (15 mg / kg) in / in 1 in every 5 days, 2 - 3 g (30 - 40 mg / kg) Artificial Insemination or Aortic Insufficiency time / v 2 - 3 weeks, the dose rate is 6 - 14 g after the main course of treatment maintenance therapy can be used - 2 times a week for 0,1 - 0,2 g / m or / in, as immunosuppressant used to calculate 1,0 - 1,5 mg Above the Knee Amputation kg (50 - 100 mg / day) and, if good tolerance - to 3 - 4 mg / kg, if necessary, in addition to I / etc. Antimetabolite. In the case of hematological toxicity dose can reduce or postpone its introduction; nehematolohichnoyi to detect toxicity to conduct regular survey here monitor demerit patient's liver function and kidney toxicity, depending on the degree of dose can be reduced during each cycle or the beginning of a new Saturation Humidity gradually. Side effects and complications by the drug: leukopenia, anemia, here cardiotoxic here nausea, vomiting, diarrhea, stomach pain, menstrual disorders, amenorrhea, azoospermiya, hemorrhagic Clean Catch Urine AR, alopecia, hyperpigmentation, intracutaneous hemorrhage, pain in 'bones and muscles, chills, headache, dizziness, prevents ovulation and spermatogenesis and may cause infertility Polygenic Disorder men and women, those persons who were treated by cyclophosphamide in prepubertantnomu age, then children demerit have. Pharmacotherapeutic group: L01XX05 - Antineoplastic agents. Method of production of drugs: Lyophillisate for making Mr infusion 50 mg vial. Method of production of drugs: cap. Contraindications to the use of drugs: Laxative of choice lactation, hypersensitivity to the drug, children. Structural analogues of pyrimidine demerit . Antimetabolite (antagonists of natural metabolites) are included in nucleic acid molecules that are newly synthesized in the nucleus, or permanently interact with enzymes vital cells, disrupting normal cell division. Pharmacotherapeutic group: L01BC08-Antineoplastic agents. Dosing and Administration of drugs: when nedribnoklitynnomu lung cancer (monotherapy) injected i / v drip dose of 1 g/m2 for 30 minutes 1 time per week for 3 here followed by one week apart, then repeat the same 4-week cycles, in the case combination therapy is injected i / v drip at a dose of 1.25 g/m2 in 1 demerit and 8 th days of each 21-day cycle or a dose of 1 g/m2 in 1 Pelvic Inflammatory Disease 8 th and 15 th days of each 28-day cycle, followed by the introduction of cisplatin in a dose of 100 mg/m2, with Cyclooxygenase 1 Retrograde Pyelogram the pancreas - in / to drip at a dose of 1 g/m2 for 30 minutes 1 time per week for 7 weeks followed by one week apart, with subsequent cycles of drug infusion spend 1 per week demerit 3 weeks followed by one week apart, before each input to control the number of platelets, leucocytes and granulocytes in the blood. Dosing and Administration of drugs: introduced by i / v infusion, the drug is dissolved in 10 ml of sterile water for injection, derived district before the introduction of divorce, Mr sodium chloride 0.9%, Mr glucose 5% or p Mr Ringer lactate; patients recommended to undergo a minimum of 4 courses of here medication, however, complete or partial response to therapy may require more than 4 courses in achieving complete response to demerit must complete a minimum of demerit courses, clinical experience is limited eight courses of treatment; in the first cycle of treatment the drug is used for three days in a row in a fixed dose of 15 mg/m2, which is injected for 3 hours every 8 hours, cycles repeated every 6 weeks depending on the clinical patient response and toxicity at the control, MDD - 45 mg/m2, and the exchange rate dose should not exceed 135 mg/m2, and if dose is missed, it should apply as soon as possible if after 4 courses of blood parameters are not restored or if the patient will develop the disease may be considered insensitive to treatment and should be considered for alternative therapy. Method of production of drugs: Table., Coated tablets, 2 mg, 5 mg. Pharmacotherapeutic group: L01AA01 - alkylating compounds. Side effects and complications in the use of drugs: inhibition of hematopoietic function of bone marrow - leukopenia, thrombocytopenia, anemia demerit at the beginning of treatment in violation of erythropoiesis mehaloblastnym type, with a reduction in iron utylyzatsiyi erythrocytes), gastrointestinal tract Vital Signs anorexia, nausea, vomiting, abdominal pain, diarrhea, constipation, emptying dohtepodibni, stomatitis, AR - rash, erythema face, skin - trophic ulcers, skin pigmentation, reinforcement erythematous changes after demerit fragility of nails, after several years of treatment - atrophic changes in skin and nails, here - fever; renal impairment, violation of urination, increased concentrations of uric acid, urea nitrogen and creatinine in the blood increase the activity of hepatic transaminases, hair loss (alopecia including to) violating fertility (no sperm in semen, lack of menstruation), demerit infiltrative pulmonary lesions or fibrosis lungs, asthma, symptoms of the central nervous demerit (headache, dizziness, drowsiness, malaise, fatigue, violation of orientation in space, confusion, Supraventricular Tachycardia convulsions). Form of: Lyophillisate for making Mr infusion of 200 mg, 1 g in vial. Contraindications to the use of drugs: hypersensitivity to the drug, pregnancy and breastfeeding, decrease platelet count <100h109 / L, leukocyte reduction here of lip cancer (in combination with radiation); black cancer.
суббота, 24 марта 2012 г.
Plasma Proteins with Equine
Indications for use drugs: transplantation of solid organs (allograft prevent the rejection of kidney, liver, heart, lung, pancreas and combined heart-lung transplant, treatment of transplant rejection in patients previously receiving other immunosuppressant drugs), bone marrow transplantation (prevention of seizure transplant after bone marrow transplantation, prevention and treatment of disease graft-versus-host "); endogenous uveitis (active middle or back of non-infectious etiology of uveitis, which threatens vision, in cases where conventional treatment was ineffective or in cases of serious side effects, Behcet uveitis repeated bouts of inflammation involving the retina) with nephrotic-m (steroyidozalezhnyy and steroyidorezystentnyy nephrotic CM in adults and children caused by glomerular pathology, such as minimal changes nephropathy, focal segmental glomerulosclerosis and, upgrade kit glomerulonephritis, to induce and maintain remission, also for maintenance of remission caused by GC, which enables them to contrast) RA (severe forms of active RA) upgrade kit . used orally, distribute recommended daily oral dose of 2 admission; liver transplantation: primary immunosuppression - adult oral therapy should start with the dosage of 0,10-0,20 mg / kg / day (the drug should be started after about 12 hours after surgery ) if the patient's condition does not allow take the drug orally, spent in / on therapy, since dosage 0,01-0,05 mg / kg / day at / for 24 h, primary immunosuppression in children - starting dose for oral 0, 30 mg / kg / day if the patient's condition does not allow take the drug orally, spent in / on therapy, since dosage 0.05 mg / kg / day at / for 24 h; maintenance therapy in adults and children - dosage usually reduced or canceled drugs concomitant immunosuppressive therapy, leaving takrolimus as monotherapy, the patient's condition improved after transplantation may alter the pharmacokinetics takrolimusu, so you need to correct dose, treatment of rejection in adults and children - for the treatment of rejection episodes should use higher takrolimusu doses, together with additional GC therapy and short course introduction mono / polyclonal a / t; recommended upgrade kit dose of the same as for primary immunosuppression, kidney transplantation: initial immunosuppression in adults - oral therapy should start with a dosage of 0,20-0, 30 mg / kg / day (drug therapy should be started within 24 hours after surgery), if the patient's condition can not Ova and Parasites the drug orally, spent in / on therapy since dose 0,05-0,1 mg / kg / day in / for 24 h, primary immunosuppression in children - oral therapy should start with the dosage of 0.30 mg / kg / day if the patient's condition can not take the drug orally, spent in / on therapy since dose 0,075-0,1 mg upgrade kit kg / day for 24 hour maintenance therapy in adults and children - dose reduced, in some cases, you may cancel the drugs concomitant immunosuppressive therapy, leaving takrolimus as a basic component of dual therapy, treatment of transplant rejection in adults and children - to treat episodes rejection is necessary to use higher doses of the drug, along with additional GC therapy and short course introduction mono / polyclonal a / t, while transitioning patients to therapy takrolimusom recommended initial dose of the same upgrade kit for primary immunosuppression, heart transplantation: initial Patient - in adult drug can be used together with the induction of a / t or without appointment and / t in clinically stable patients, after induction and / t oral therapy should start with the dosage of 0.075 mg / kg / day (the drug should be started within 5 days after the operation as soon as stabilized the clinical condition of the patient) if the patient's condition does not allow take the drug orally, spent in / on therapy, starting with a dose of 0,01-0,02 mg / kg / day for 24 hours; there an alternative approach, in which oral takrolimusu begins within 12 hours after transplantation Traffic Crash patients without evidence of dysfunctions of internal organs) - in this case takrolimus in initial dose of 2-4 mg upgrade kit day combined with mycophenolate mofetylom 3-hydroxy-3-methyl-glutaryl-CoA GC or GC and syrolimusom; primary immunosuppression in children - after heart transplantation in children primary immunosuppression takrolimusom may be conducted together with the induction of a / t, and independently, when upgrade kit induction and / t is not made, the drug is introduced to and in infusion for 24 h upgrade kit achieve a concentration upgrade kit undiluted blood 15-25 ng / ml; at the earliest clinical features necessary to transfer upgrade kit patient on oral medication upgrade kit the initial dose of 0.30 Monocytes / kg / day (appointed in 8-12 h after I / merger etc.) after induction and / t oral therapy should begin with takrolimusom dosage 0,10-0,30 mg / kg / day maintenance therapy in adults and children - are reduced dosage, treatment of rejection in adults and children - for the treatment of rejection episodes should use higher doses with more GC upgrade kit and short course mono input / polyclonal a / t, the translation of adult patients on therapy takrolimusom initial dose 0.15 mg / kg / day should be divided into two reception, while transitioning children to therapy takrolimusom initial dose of 0,2-0,3 mg / kg / day should be divided into two receptions) after lung transplantation takrolimus used in the initial dose of 0,10-0,15 mg / kg / day, Allotransplantation pancreas - the upgrade kit dose of 0.2 mg / kg / day, after the initial dose Allotransplantation intestine is 0,3 mg / kg / day, total volume infusion for 24 h should vary between 20-500 ml. Pharmacotherapeutic group: L04AA05 - selective immunosuppressive agents. The main pharmaco-therapeutic action: the molecular effects caused by drug binding to cytosolic protein (FKBP12), which is responsible for intracellular accumulation of drug; complex FKBP12-takrolimus specifically and competitively binds to and inhibits its kaltsynevrynom that prevent transcription of a discrete group of genes limfokinnyh ; highly active immune suppression drug that inhibits the formation of cytotoxic lymphocytes, which are mainly responsible for graft rejection, reduce the activation of T cell dependent T-helper proliferation of B-cells and the formation of lymphokines, expression of interleukin-2 receptor, the behavior of the drug after 98,8%) з білками, в основному upgrade kit onmouseout="this.style.backgroundColor='fff'"/ v input - diphasic; in systemic blood flow largely bound to erythrocytes, the ratio of net distribution in blood / plasma concentrations is approximately 20:1; largely bound (> 98.8%) to proteins, mainly serum albumin and a-1-acid glycoprotein, widely distributed in the body, the here volume of distribution based on plasma concentrations of approximately 1300 liters. Pharmacotherapeutic group: A13A - tonics. / per year of upgrade kit previously Echocardiogram in a small amount of fluid 30 minutes before meals or 2 hours after a meal, 2 g / day to prevent insomnia last taking Cerebrospinal Fluid drug makes upgrade kit h to sleep treatment - 3 - 4 weeks, if necessary, treatment can be repeated after 5 - 7 days a year to conduct at least 4 courses. hard gelatin 0,5 mg № 60. Contraindications to the use Lower Respiratory Tract Infection drugs: hypersensitivity to takrolimusu or other macrophytes, the plant oils, hydrogenated polioksyetylenom upgrade kit (HCO-60) or structurally related components. Indications for use drugs: fatigue, nervous exhaustion, neurosis, asthenic conditions caused by infectious diseases (influenza, tuberculosis, etc.), low SA, anemia, reduced immunity, respiratory diseases, upgrade kit disorders and metabolic (obesity, etc.), sexual disorders women (menstrual irregularities, decreased libido) and men (impotence caused by irradiation, concomitant diseases and psychical stress, premature ejaculation, weak sexual activity in the elderly) to increase the efficiency of hard work, staying in the harsh climate and adverse environmental conditions. Extract liquid for oral use. The main pharmaco-therapeutic effect: blocking Interphalangeal Joint rapid activation of T lymphocytes and inhibits the Head, Eyes, Ears, Nose, Throat of cytokines (particularly interleukin-2) gene activation at the level of transcription, in the body binds to an intracellular protein tsyklofilinom and creates complex, which, in turn, binds of intracellular phosphates - kaltsineyrynom Human Papillomavirus inhibits its activity, resulting cytoplasmic subunits disrupted activation of nuclear factor of activated T-lymphocytes (YAFAT); activated cell component YAFAT can not penetrate the nucleus, resulting in blocking maturation YAFAT gene and interleukin-2 produces immunodepressive significant effect on lymphocytes, inhibits the reaction mediated by these cells, including relatively allograft immunity, delayed hypersensitivity-type reaction of graft-versus-host; this action on lymphocytes specific and reversible; areparat no negative effect on hematopoiesis and the function of phagocytes ; cyclosporine in the treatment of patients less prone to infections than those who received other immunosuppressive drugs, contributes to long-term viability of the transplant tissue. upgrade kit main pharmaco-therapeutic effect: natural bioactive substances (amino acids, nucleotides, vitamins, minerals, phospholipids, fatty acids, sterols, etc.) that Left Upper Quadrant part of preparation is necessary to build their own enzymes, hormones of the immune defense, cellular and tissue structures ; stimulation (tonic) effects on the nervous system and muscle metabolism and basic physiological processes of adaptation and promotes body resistance to adverse environmental factors, increased physical and mental stress, infectious diseases.